Revenio Group Corporation: Revenio cancels its Annual General Meeting and moves it to a later date

Revenio Group Corporation, Stock Exchange Release, March 17, 2020 at 9:50

Revenio cancels its Annual General Meeting and moves it to a later date

Based on the development of the coronavirus situation and the announcement by the Finnish Government, Revenio has decided to cancel its Annual General Meeting of 19 March 2020 at 16:00.

The Finnish Government has announced that public gatherings will be limited to a maximum of ten persons. Consequently, Revenio’s Board of Directors has today decided to cancel the Annual General Meeting 2020 from Thursday.

Revenio will convene the Annual General Meeting at a later stage.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

www.revenio.fi 

The Revenio Group in brief

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group’s focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.